Sociedad Americana de Hirudoterapia

Hemorrhagic, coagulant and fibrino(geno)lytic activities of crude venom and fractions from mapanare (Bothrops colombiensis) snakes

Research article published in Comparative biochemistry and physiology Toxicology & pharmacology (2007)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Observational studyDesarrollo de fármacosGiron ME et al. · Comparative biochemistry and physiology Toxicology & pharmacology, 2007

Abstract

Bothrops colombiensis venom from two similar geographical locations were tested for their hemostatic functions and characterized by gel-filtration chromatography and SDS-PAGE electrophoresis. The snakes were from Caucagua and El Guapo towns of the Venezuelan state of Miranda. Fibrino(geno)lytic, procoagulant, hemorrhagic, lethal activities, gel-filtration chromatography and SDS-PAGE profiles were analyzed and compared for both venoms. The highest hemorrhagic activity of 5.3 mug was seen in El Guapo venom while Caucagua venom had the lowest LD(50) of 5.8 mg/kg. Both venoms presented similar thrombin-like activity. El Guapo showed a factor Xa-like activity two times higher than Caucagua. Differences were observed in kallikrein-like and t-PA activities, being highest in El Guapo. Caucagua venom showed the maximum fibrin lysis. Both crude venom runs on Sephadex G-100 chromatography gave fraction SII with the high fibrinolytic activity. Proteases presented in SII fractions and eluted from Benzamidine-Sepharose (not bound to the column) provoked a fast degradation of fibrinogen alpha chains and a slower degradation of beta chains, which could possibly be due to a higher content of alpha fibrinogenases in these venoms. The fibrinogenolytic activity was decreased by metalloprotease inhibitors. The results suggested that metalloproteases in SII fractions were responsible for the fibrinolytic activity. The analysis of samples for fibrin-zymography of SII fractions showed an active band with a molecular mass of approximately 30 kDa. These results reiterate the importance of using pools of venoms for antivenom immunization, to facilitate the neutralization of the maximum potential number of toxins.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleMulticenter StudyResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBlood CoagulationBothropsChromatography, GelCrotalid VenomsDextransElectrophoresis, Polyacrylamide GelFactor XaFibrinFibrinogenFibrinolysisHemorrhage

Resumen

Hemorrhagic, coagulant and fibrino(geno)lytic activities of crude venom and fractions from mapanare (Bothrops colombiensis) snakes.

Por qué esto importa para la hirudoterapia

Este estudio analizó y comparó las actividades hemorrágica, coagulante y fibrino(geno)lítica del veneno crudo de serpientes Bothrops colombiensis recolectadas en dos municipios venezolanos vecinos. Los investigadores identificaron niveles variables de actividades tipo trombina, tipo factor Xa y fibrinolíticas mediadas por metaloproteasas entre las muestras geográficas, señalando en última instancia la importancia de utilizar venenos agrupados (pooled) para la inmunización con antivenenos. Si bien la investigación examina de forma extensa las alteraciones hemostáticas y las enzimas proteolíticas implicadas en la coagulación sanguínea, se enfoca estrictamente en caracterizar la toxicidad del veneno de serpiente. Por lo tanto, el resumen no aporta información relevante para la hirudoterapia, el secretoma de la sanguijuela ni las aplicaciones terapéuticas de las sanguijuelas medicinales.

Citación

Hemorrhagic, coagulant and fibrino(geno)lytic activities of crude venom and fractions from mapanare (Bothrops colombiensis) snakes

Giron ME et al. · Comparative biochemistry and physiology Toxicology & pharmacology, 2007

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.